RU2013142437A - Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных - Google Patents
Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных Download PDFInfo
- Publication number
- RU2013142437A RU2013142437A RU2013142437/15A RU2013142437A RU2013142437A RU 2013142437 A RU2013142437 A RU 2013142437A RU 2013142437/15 A RU2013142437/15 A RU 2013142437/15A RU 2013142437 A RU2013142437 A RU 2013142437A RU 2013142437 A RU2013142437 A RU 2013142437A
- Authority
- RU
- Russia
- Prior art keywords
- animal
- damage
- nervous system
- ufa
- component
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 142
- 241001465754 Metazoa Species 0.000 title claims abstract 123
- 230000006378 damage Effects 0.000 title claims abstract 108
- 239000000203 mixture Substances 0.000 title claims 27
- 230000002265 prevention Effects 0.000 title claims 3
- 230000009467 reduction Effects 0.000 title claims 2
- 210000000653 nervous system Anatomy 0.000 claims abstract 49
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract 45
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract 45
- 210000004498 neuroglial cell Anatomy 0.000 claims abstract 21
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract 16
- 210000004027 cell Anatomy 0.000 claims abstract 12
- 210000002569 neuron Anatomy 0.000 claims abstract 10
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract 8
- 208000003098 Ganglion Cysts Diseases 0.000 claims abstract 7
- 102000006386 Myelin Proteins Human genes 0.000 claims abstract 7
- 108010083674 Myelin Proteins Proteins 0.000 claims abstract 7
- 208000005400 Synovial Cyst Diseases 0.000 claims abstract 7
- 210000005012 myelin Anatomy 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 210000004116 schwann cell Anatomy 0.000 claims abstract 5
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims abstract 5
- 210000003050 axon Anatomy 0.000 claims abstract 3
- 210000004556 brain Anatomy 0.000 claims abstract 3
- 210000005056 cell body Anatomy 0.000 claims abstract 3
- 210000001787 dendrite Anatomy 0.000 claims abstract 3
- 239000012636 effector Substances 0.000 claims abstract 3
- 208000014674 injury Diseases 0.000 claims abstract 3
- 210000000278 spinal cord Anatomy 0.000 claims abstract 3
- 210000000225 synapse Anatomy 0.000 claims abstract 3
- 210000001130 astrocyte Anatomy 0.000 claims abstract 2
- 210000000274 microglia Anatomy 0.000 claims abstract 2
- 210000004248 oligodendroglia Anatomy 0.000 claims abstract 2
- 239000003963 antioxidant agent Substances 0.000 claims 23
- 235000006708 antioxidants Nutrition 0.000 claims 23
- 235000019156 vitamin B Nutrition 0.000 claims 22
- 239000011720 vitamin B Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 19
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 15
- 239000001961 anticonvulsive agent Substances 0.000 claims 14
- 229960003965 antiepileptics Drugs 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 235000013305 food Nutrition 0.000 claims 9
- 208000028389 Nerve injury Diseases 0.000 claims 8
- 230000032683 aging Effects 0.000 claims 7
- 230000001773 anti-convulsant effect Effects 0.000 claims 7
- 239000000935 antidepressant agent Substances 0.000 claims 7
- 239000003246 corticosteroid Substances 0.000 claims 7
- 239000003018 immunosuppressive agent Substances 0.000 claims 7
- 229940124589 immunosuppressive drug Drugs 0.000 claims 7
- 235000020938 metabolic status Nutrition 0.000 claims 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims 7
- 230000009885 systemic effect Effects 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 229960003121 arginine Drugs 0.000 claims 6
- 229960002173 citrulline Drugs 0.000 claims 6
- 235000013477 citrulline Nutrition 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229960003104 ornithine Drugs 0.000 claims 6
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 5
- 102000003951 Erythropoietin Human genes 0.000 claims 5
- 108090000394 Erythropoietin Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 5
- 108700011259 MicroRNAs Proteins 0.000 claims 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 5
- 239000003557 cannabinoid Substances 0.000 claims 5
- 229930003827 cannabinoid Natural products 0.000 claims 5
- 229940105423 erythropoietin Drugs 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 5
- 229960004194 lidocaine Drugs 0.000 claims 5
- 229960003404 mexiletine Drugs 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- -1 neurotropin Substances 0.000 claims 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 5
- 229930002330 retinoic acid Natural products 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229940084026 sodium valproate Drugs 0.000 claims 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 5
- 229960001727 tretinoin Drugs 0.000 claims 5
- 229960000604 valproic acid Drugs 0.000 claims 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- 208000001738 Nervous System Trauma Diseases 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 4
- 150000001483 arginine derivatives Chemical class 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 3
- 239000002417 nutraceutical Substances 0.000 claims 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- 229930003231 vitamin Natural products 0.000 claims 3
- 235000013343 vitamin Nutrition 0.000 claims 3
- 239000011782 vitamin Substances 0.000 claims 3
- 229940088594 vitamin Drugs 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 2
- 101150036143 NTF3 gene Proteins 0.000 claims 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 229960000623 carbamazepine Drugs 0.000 claims 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 235000019197 fats Nutrition 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 230000033001 locomotion Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 230000007659 motor function Effects 0.000 claims 2
- 229960002036 phenytoin Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 229960001233 pregabalin Drugs 0.000 claims 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000037152 sensory function Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 230000036642 wellbeing Effects 0.000 claims 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 1
- 235000013793 astaxanthin Nutrition 0.000 claims 1
- 239000001168 astaxanthin Substances 0.000 claims 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims 1
- 229940022405 astaxanthin Drugs 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091008690 chemoreceptors Proteins 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108091008699 electroreceptors Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000007166 healthy aging Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000412 mechanoreceptor Anatomy 0.000 claims 1
- 108091008704 mechanoreceptors Proteins 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000007383 nerve stimulation Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 229960003753 nitric oxide Drugs 0.000 claims 1
- 210000000929 nociceptor Anatomy 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 238000000053 physical method Methods 0.000 claims 1
- 238000002616 plasmapheresis Methods 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 235000011649 selenium Nutrition 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 229940091258 selenium supplement Drugs 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 210000003051 thermoreceptor Anatomy 0.000 claims 1
- 108091008689 thermoreceptors Proteins 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- 235000010930 zeaxanthin Nutrition 0.000 claims 1
- 239000001775 zeaxanthin Substances 0.000 claims 1
- 229940043269 zeaxanthin Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Birds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161463594P | 2011-02-18 | 2011-02-18 | |
| US61/463,594 | 2011-02-18 | ||
| PCT/US2012/024137 WO2012112340A2 (en) | 2011-02-18 | 2012-02-07 | Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013142437A true RU2013142437A (ru) | 2015-03-27 |
Family
ID=46673093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142437/15A RU2013142437A (ru) | 2011-02-18 | 2012-02-07 | Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130324608A1 (https=) |
| EP (1) | EP2675447A4 (https=) |
| JP (1) | JP2014514248A (https=) |
| CN (1) | CN103764136A (https=) |
| AU (1) | AU2012218094A1 (https=) |
| BR (1) | BR112013020802A2 (https=) |
| CA (1) | CA2827715A1 (https=) |
| MX (1) | MX2013009544A (https=) |
| RU (1) | RU2013142437A (https=) |
| WO (1) | WO2012112340A2 (https=) |
| ZA (1) | ZA201306990B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014108808A2 (en) * | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| WO2014116985A1 (en) * | 2013-01-25 | 2014-07-31 | Winning The Fight Inc. | Composition for treatment of neurodegenerative disease |
| UA117274C2 (uk) * | 2013-12-19 | 2018-07-10 | Тасос Гєоргіу | Спосіб лікування, зменшення інтенсивності або профілактити захворювань, обумовлених ураженням зорового нерва |
| CN104146253A (zh) * | 2014-08-13 | 2014-11-19 | 胡安然 | 癫痫全营养配方食品 |
| JP7457505B2 (ja) | 2017-05-10 | 2024-03-28 | ユニバーシティー オブ ロチェスター | 神経精神障害を処置する方法 |
| CN109300527A (zh) * | 2018-12-14 | 2019-02-01 | 苏州大学 | 饮食信息的推荐方法 |
| US20230016955A1 (en) * | 2020-06-01 | 2023-01-19 | Corona Feed Additives, L.L.C. | Animal Contraceptive |
| EP4153183A4 (en) * | 2020-06-01 | 2024-08-07 | Corona Feed Additives, L.L.C. | COMPOSITION, SYSTEM AND METHOD OF PIG CONTRACEPTION |
| AU2021291569A1 (en) * | 2020-06-16 | 2022-10-20 | Md Healthcare Inc. | Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from lactobacillus paracasei |
| CN113368171A (zh) * | 2021-06-18 | 2021-09-10 | 长江大学 | 枸杞在预防放射治疗导致的认知功能障碍药物中的应用 |
| CN113322213B (zh) * | 2021-07-09 | 2022-05-13 | 吉林大学 | 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5883087A (en) * | 1991-01-07 | 1999-03-16 | Pherin Corporation | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US5308832A (en) * | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
| WO1998008500A1 (en) * | 1996-08-26 | 1998-03-05 | Board Of Regents, The University Of Texas System | Hypertonic arginine compositions and methods |
| CA2270795A1 (en) * | 1999-05-05 | 2000-11-05 | Gestilab Inc. | Neuroprotective compositions and uses thereof |
| IL147112A0 (en) * | 1999-06-14 | 2002-08-14 | Ford Henry Health System | Nitric oxide donors for inducing neurogenesis |
| US7135498B1 (en) * | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US6469049B1 (en) * | 2000-04-21 | 2002-10-22 | The United States Of America As Represented By The Secretary Of The Army | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
| US7563862B2 (en) * | 2001-08-24 | 2009-07-21 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and methods for their use in treatment of brain damage |
| WO2003032804A2 (en) * | 2001-10-12 | 2003-04-24 | Cornell Research Foundation, Inc. | Reversing or preventing premature vascular senescence |
| JP2003261456A (ja) * | 2002-03-08 | 2003-09-16 | Howaizu:Kk | 脳の老化予防剤 |
| WO2007008690A2 (en) * | 2005-07-08 | 2007-01-18 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2 |
| US20040186488A1 (en) * | 2003-03-17 | 2004-09-23 | Droese Karl William | Method of peripheral nerve reconstruction using a micro suction connector |
| US6951658B1 (en) * | 2003-07-08 | 2005-10-04 | Pearson Research & Development Limited | Emu-based compositions for mental well-being and method of use |
| CA2598525A1 (en) * | 2005-02-22 | 2006-08-31 | Mochida Pharmaceutical Co., Ltd. | Nerve regeneration promoting agent |
| US20100254951A1 (en) * | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
| US20080103092A1 (en) * | 2005-03-11 | 2008-05-01 | Pomytkin Igor A | Methods for Intradermal, Transdermal or Transmucosal Delivery of Biologically Active Substances |
| EP1919304B1 (en) * | 2005-08-26 | 2011-05-25 | Nestec S.A. | Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis after an ischemic episode in the brain |
| ES2365628T3 (es) * | 2005-08-26 | 2011-10-07 | Nestec S.A. | Composiciones y métodos para mejorar la integridad vascular funcional, la supervivencia celular y la reducción de la apoptosis después de un episodio isquémico en el cerebro. |
| WO2007050318A2 (en) * | 2005-10-24 | 2007-05-03 | Duke University | Lipidomics approaches for central nervous system disorders |
| CA2994586C (en) | 2008-01-04 | 2020-07-21 | Nestec S.A. | Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions |
| US20090214484A1 (en) * | 2008-02-22 | 2009-08-27 | Nikolay Mironov | Stem cell therapy for the treatment of central nervous system disorders |
-
2012
- 2012-02-07 JP JP2013554477A patent/JP2014514248A/ja active Pending
- 2012-02-07 MX MX2013009544A patent/MX2013009544A/es unknown
- 2012-02-07 EP EP12747397.3A patent/EP2675447A4/en not_active Withdrawn
- 2012-02-07 WO PCT/US2012/024137 patent/WO2012112340A2/en not_active Ceased
- 2012-02-07 AU AU2012218094A patent/AU2012218094A1/en not_active Abandoned
- 2012-02-07 RU RU2013142437/15A patent/RU2013142437A/ru unknown
- 2012-02-07 CA CA2827715A patent/CA2827715A1/en not_active Abandoned
- 2012-02-07 CN CN201280018853.7A patent/CN103764136A/zh active Pending
- 2012-02-07 US US13/985,884 patent/US20130324608A1/en not_active Abandoned
- 2012-02-07 BR BR112013020802A patent/BR112013020802A2/pt not_active IP Right Cessation
-
2013
- 2013-09-17 ZA ZA2013/06990A patent/ZA201306990B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013020802A2 (pt) | 2016-10-04 |
| WO2012112340A2 (en) | 2012-08-23 |
| AU2012218094A1 (en) | 2013-08-29 |
| EP2675447A2 (en) | 2013-12-25 |
| JP2014514248A (ja) | 2014-06-19 |
| MX2013009544A (es) | 2013-09-26 |
| EP2675447A4 (en) | 2015-04-22 |
| WO2012112340A3 (en) | 2014-04-17 |
| US20130324608A1 (en) | 2013-12-05 |
| ZA201306990B (en) | 2015-04-29 |
| CA2827715A1 (en) | 2012-08-23 |
| CN103764136A (zh) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013142437A (ru) | Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных | |
| EP2667882B1 (en) | Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals | |
| RU2010132637A (ru) | Композиции, включающие ненасыщенные жирные кислоты и соединения, высбождающие оксид азота, и их применение для усиления когнитивной функции и связанных с ней функцией | |
| JP6301655B2 (ja) | 健康な皮膚の促進に適した方法及び組成物 | |
| JP6820868B2 (ja) | 動物において神経新生を増強するための組成物及び方法 | |
| CN101820754A (zh) | 用于增强认知功能的组合物与方法 | |
| JP2014515011A (ja) | 加齢に伴う疾病を改善するのに有用な組成物及び方法 | |
| US10668041B2 (en) | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy | |
| AU2015358958B2 (en) | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy | |
| US11284633B2 (en) | Pet food composition for managing non-food allergies | |
| CA2731580A1 (en) | Methods and compositions for preventing, reducing, or treating damage caused by ischemia and ischemia-like conditions |